Therapy Directory

Azacitidine clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Azacitidine as a study intervention. Browse Azacitidine recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

695

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Acute Myeloid Leukemia
Interventions: guadecitabine, Treatment Choice (TC); Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 15
States / cities: Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 11 more

Conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Interventions: ASTX727, Dacogen; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 39
States / cities: Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more

Conditions: Myelodysplastic Syndrome, MDS
Interventions: ASTX727 Dose Escalation, ASTX727 Dose Confirmation, ASTX727 Fixed-Dose Combination; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 9 more

Conditions: Leukemia, Myeloid, Acute
Interventions: SGI-110 (guadecitabine), Treatment Choice; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 815 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 23
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 18 more

Conditions: Lymphoid Malignancies, Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
Interventions: RomiDEPsin 10 MG/M2, Oral 5-Azacitidine 100 MG, Romidepsin 14 MG/M2, Oral 5-Azacitidine 200 MG, Oral 5-Azacitidine 300 MG; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Interventions: ASTX727 + Day 2 Food, ASTX727 + Day 4 Food; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Buffalo, New York • Canton, Ohio • Nashville, Tennessee + 1 more

Conditions: Myelodysplastic Syndrome
Interventions: decitabine (5-aza-2'deoxycytidine); Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 24
States / cities: Berkeley, California • Duarte, California • Escondido, California + 17 more

Conditions: Chronic Myelogenous Leukemia
Interventions: decitabine (5-aza-2'deoxycytidine); Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 7
States / cities: Duarte, California • Escondido, California • Los Angeles, California + 4 more

Conditions: Acute Myeloid Leukemia
Interventions: Crenolanib besylate, Idarubicin, Cytarabine, Azacytidine, Mitoxantrone, Etoposide, Fludarabine, G-CSF; Drug
Lead sponsor: Arog Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions: INQOVI (decitabine and cedazuridine), Nivolumab; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Myelodysplastic Syndromes
Interventions: Magrolimab, Azacitidine, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 539 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 47
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 32 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Venetoclax, Decitabine, Fludarabine, Busulfan, Total Body Irradiation; Drug · Radiation
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

About this Azacitidine clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Azacitidine as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Azacitidine.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Azacitidine clinical trials

Filter and sort this therapy

Live official records

Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

Effect of Food on Blood Levels of ASTX727

Decitabine Versus Supportive Care in Adults With Advanced-stage MDS

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)

Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

About this Azacitidine clinical trials directory page